Ranpirnase

Drug Profile

Ranpirnase

Alternative Names: Amphibian ribonuclease A; Onconase; P-30 protein - Alfacell; P-30 ribonuclease

Latest Information Update: 09 Mar 2017

Price : $50

At a glance

  • Originator Alfacell Corporation
  • Developer Alfacell Corporation; Tamir Biotechnology
  • Class Antineoplastics; Ribonucleases
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Protein synthesis inhibitors; Ribonuclease stimulants; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Mesothelioma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Genital warts; Human papillomavirus infections
  • Preclinical Ebola virus infections; Zika virus infection
  • Discontinued Acute myeloid leukaemia; Brain cancer; Chronic lymphocytic leukaemia; HIV infections; Mesothelioma; Neuroblastoma; Pancreatic cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 08 Mar 2017 Efficacy data from a phase I/II trial in Genital warts and Human papillomavirus infections released by Tamir Biotechnology
  • 01 Sep 2016 Tamir Biotechnology completes a phase I/II trial in Genital warts and Human papillomavirus infections in Bolivia (NCT02535104)
  • 28 Jul 2016 Pharmacoynamic data from preclinical trials in Ebola virus infections released by Tamir Biotechnology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top